Our study showed that the delivery of siAPE1 by PSMA-targeted therapeutic nanoparticles (Mel@PSMA-R12-125I) might be an effective treatment for PCa because it efficiently suppressed in vitro PCa cell proliferation and in vivo PCa tumor growth. The gene discussed is FOLH1; the disease is posterior cortical atrophy.